{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:42:17Z","timestamp":1784612537867,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,23]],"date-time":"2025-09-23T00:00:00Z","timestamp":1758585600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"the 2022 Pharmaceutical Research Fund of Guangdong Province Hospital Association","award":["2022YXKY15"],"award-info":[{"award-number":["2022YXKY15"]}]},{"name":"the Foundation from The State Key Laboratory of Respiratory Disease","award":["SKLRD-QN-201710"],"award-info":[{"award-number":["SKLRD-QN-201710"]}]},{"name":"the Foundation from Guangzhou Institute of Respiratory Health","award":["2019 GIRHZ04"],"award-info":[{"award-number":["2019 GIRHZ04"]}]},{"name":"ZHONGNANSHAN Medical Foundation of Guangdong Province","award":["ZNSA-2020013"],"award-info":[{"award-number":["ZNSA-2020013"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00228-025-03920-9","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T22:58:58Z","timestamp":1758581938000},"page":"1841-1852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Population pharmacokinetic characteristics of tacrolimus in Chinese lung transplant recipients and optimisation of dosing regimen during the early post-transplantation phase"],"prefix":"10.1007","volume":"81","author":[{"given":"Shouning","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiaoyan","family":"Lian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huilong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunrong","family":"Ju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,9,23]]},"reference":[{"issue":"2","key":"3920_CR1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.healun.2004.02.022","volume":"24","author":"H Reichenspurner","year":"2005","unstructured":"Reichenspurner H (2005) Overview of tacrolimus-based immunosuppression after heart or lung transplantation. J Heart Lung Transplant 24(2):119\u2013130. https:\/\/doi.org\/10.1016\/j.healun.2004.02.022","journal-title":"J Heart Lung Transplant"},{"issue":"10","key":"3920_CR2","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.healun.2019.08.001","volume":"38","author":"DC Chambers","year":"2019","unstructured":"Chambers DC, Cherikh WS, Harhay MO, Hayes D Jr., Hsich E, Khush KK, Meiser B, Potena L, Rossano JW, Toll AE, Singh TP, Sadavarte A, Zuckermann A, Stehlik J (2019) The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: thirty-sixth adult lung and heart-lung transplantation report-2019; focus theme: donor and recipient size match. J Heart Lung Transplant 38(10):1042\u20131055. https:\/\/doi.org\/10.1016\/j.healun.2019.08.001","journal-title":"J Heart Lung Transplant"},{"issue":"3","key":"3920_CR3","doi-asserted-by":"publisher","first-page":"186","DOI":"10.4103\/atm.ATM_160_18","volume":"14","author":"JH Ryu","year":"2019","unstructured":"Ryu JH, Choi S, Lee HJ, Kim YT, Kim YW, Yang J (2019) Low early posttransplant serum tacrolimus levels are associated with poor patient survival in lung transplant patients. Ann Thorac Med 14(3):186\u2013191. https:\/\/doi.org\/10.4103\/atm.ATM_160_18","journal-title":"Ann Thorac Med"},{"issue":"5","key":"3920_CR4","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1007\/s00228-017-2204-8","volume":"73","author":"MA Sikma","year":"2017","unstructured":"Sikma MA, Hunault CC, van de Graaf EA, Verhaar MC, Kesecioglu J, de Lange DW, Meulenbelt J (2017) High tacrolimus blood concentrations early after lung transplantation and the risk of kidney injury. Eur J Clin Pharmacol 73(5):573\u2013580. https:\/\/doi.org\/10.1007\/s00228-017-2204-8","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3920_CR5","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/j.transproceed.2017.07.013","volume":"49","author":"S Ivulich","year":"2017","unstructured":"Ivulich S, Dooley M, Kirkpatrick C, Snell G (2017) Clinical challenges of tacrolimus for maintenance immunosuppression post-lung transplantation. Transplant Proc 49(9):2153\u20132160. https:\/\/doi.org\/10.1016\/j.transproceed.2017.07.013","journal-title":"Transplant Proc"},{"key":"3920_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9072193","author":"C Thongprayoon","year":"2020","unstructured":"Thongprayoon C, Hansrivijit P, Kovvuru K, Kanduri SR, Bathini T, Pivovarova A, Smith JR, Cheungpasitporn W (2020) Impacts of high intra- and inter-individual variability in tacrolimus pharmacokinetics and fast tacrolimus metabolism on outcomes of solid organ transplant recipients. J Clin Med. https:\/\/doi.org\/10.3390\/jcm9072193","journal-title":"J Clin Med"},{"issue":"3","key":"3920_CR7","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/FTD.0000000000000640","volume":"41","author":"M Brunet","year":"2019","unstructured":"Brunet M, van Gelder T, \u00c5sberg A, Haufroid V, Hesselink DA, Langman L, Lemaitre F, Marquet P, Seger C, Shipkova M, Vinks A, Wallemacq P, Wieland E, Woillard JB, Barten MJ, Budde K, Colom H, Dieterlen MT, Elens L, Johnson-Davis KL, Kunicki PK, MacPhee I, Masuda S, Mathew BS, Mill\u00e1n O, Mizuno T, Moes DAR, Monchaud C, Noceti O, Pawinski T, Picard N, van Schaik R, Sommerer C, Vethe NT, de Winter B, Christians U, Bergan S (2019) Therapeutic drug monitoring of Tacrolimus-personalized therapy: second consensus report. Ther Drug Monit 41(3):261\u2013307","journal-title":"Ther Drug Monit"},{"issue":"7","key":"3920_CR8","doi-asserted-by":"publisher","first-page":"419","DOI":"10.2165\/11317230-000000000-00000","volume":"48","author":"C Monchaud","year":"2009","unstructured":"Monchaud C, Marquet P (2009) Pharmacokinetic optimization of immunosuppressive therapy in thoracic transplantation: part I. Clin Pharmacokinet 48(7):419\u2013462. https:\/\/doi.org\/10.2165\/11317230-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3920_CR9","doi-asserted-by":"publisher","first-page":"421","DOI":"10.2217\/pgs-2019-0002","volume":"20","author":"AL Pasternak","year":"2019","unstructured":"Pasternak AL, Kidwell KM, Dempsey JM, Gersch CL, Pesch A, Sun Y, Rae JM, Hertz DL, Park JM (2019) Impact of CYP3A5 phenotype on tacrolimus concentrations after sublingual and oral administration in lung transplant. Pharmacogenomics 20(6):421\u2013432. https:\/\/doi.org\/10.2217\/pgs-2019-0002","journal-title":"Pharmacogenomics"},{"issue":"8","key":"3920_CR10","doi-asserted-by":"publisher","first-page":"e13332","DOI":"10.1111\/ctr.13332","volume":"32","author":"DR Calabrese","year":"2018","unstructured":"Calabrese DR, Florez R, Dewey K, Hui C, Torgerson D, Chong T, Faust H, Rajalingam R, Hays SR, Golden JA, Kukreja J, Singer JP, Greenland JR (2018) Genotypes associated with tacrolimus pharmacokinetics impact clinical outcomes in lung transplant recipients. Clin Transplant 32(8):e13332. https:\/\/doi.org\/10.1111\/ctr.13332","journal-title":"Clin Transplant"},{"issue":"9","key":"3920_CR11","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/bcp.13980","volume":"85","author":"S Anutrakulchai","year":"2019","unstructured":"Anutrakulchai S, Pongskul C, Kritmetapak K, Limwattananon C, Vannaprasaht S (2019) Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients. Br J Clin Pharmacol 85(9):1964\u20131973. https:\/\/doi.org\/10.1111\/bcp.13980","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"3920_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/cpt.113","volume":"98","author":"KA Birdwell","year":"2015","unstructured":"Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ, Leeder JS, van Schaik R, Thummel KE, Klein TE, Caudle KE, MacPhee IA (2015) Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for CYP3a5 genotype and tacrolimus dosing. Clin Pharmacol Ther 98(1):19\u201324. https:\/\/doi.org\/10.1002\/cpt.113","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"3920_CR13","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1007\/s40262-020-00922-x","volume":"59","author":"R Kirubakaran","year":"2020","unstructured":"Kirubakaran R, Stocker SL, Hennig S, Day RO, Carland JE (2020) Population pharmacokinetic models of tacrolimus in adult transplant recipients: a systematic review. Clin Pharmacokinet 59(11):1357\u20131392. https:\/\/doi.org\/10.1007\/s40262-020-00922-x","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3920_CR14","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s13318-019-00591-7","volume":"45","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Hunault CC, Van Maarseveen EM, Huitema ADR, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW (2020) High variability of whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation. Eur J Drug Metab Pharmacokinet 45(1):123\u2013134. https:\/\/doi.org\/10.1007\/s13318-019-00591-7","journal-title":"Eur J Drug Metab Pharmacokinet"},{"issue":"12","key":"3920_CR15","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.2165\/00003088-200544120-00010","volume":"44","author":"F Saint-Marcoux","year":"2005","unstructured":"Saint-Marcoux F, Knoop C, Debord J, Thiry P, Rousseau A, Estenne M, Marquet P (2005) Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet 44(12):1317\u20131328","journal-title":"Clin Pharmacokinet"},{"issue":"3","key":"3920_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/11594760-000000000-00000","volume":"51","author":"C Monchaud","year":"2012","unstructured":"Monchaud C, de Winter BC, Knoop C, Estenne M, Reynaud-Gaubert M, Pison C, Stern M, Kessler R, Guillemain R, Marquet P, Rousseau A (2012) Population pharmacokinetic modelling and design of a Bayesian estimator for therapeutic drug monitoring of tacrolimus in lung transplantation. Clin Pharmacokinet 51(3):175\u2013186. https:\/\/doi.org\/10.2165\/11594760-000000000-00000","journal-title":"Clin Pharmacokinet"},{"key":"3920_CR17","doi-asserted-by":"publisher","first-page":"105448","DOI":"10.1016\/j.ejps.2020.105448","volume":"152","author":"X Cai","year":"2020","unstructured":"Cai X, Song H, Jiao Z, Yang H, Zhu M, Wang C, Wei D, Shi L, Wu B, Chen J (2020) Population pharmacokinetics and dosing regimen optimization of tacrolimus in Chinese lung transplant recipients. Eur J Pharm Sci 152:105448. https:\/\/doi.org\/10.1016\/j.ejps.2020.105448","journal-title":"Eur J Pharm Sci"},{"issue":"4","key":"3920_CR18","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bcpt.13944","volume":"133","author":"P Tveden-Nyborg","year":"2023","unstructured":"Tveden-Nyborg P, Bergmann TK, Jessen N, Simonsen U, Lykkesfeldt J (2023) BCPT 2023 policy for experimental and clinical studies. Basic Clin Pharmacol Toxicol 133(4):391\u2013396. https:\/\/doi.org\/10.1111\/bcpt.13944","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"4","key":"3920_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jpba.2010.06.022","volume":"53","author":"C Bazin","year":"2010","unstructured":"Bazin C, Guinedor A, Barau C, Gozalo C, Grimbert P, Duvoux C, Furlan V, Massias L, Hulin A (2010) Evaluation of the architect tacrolimus assay in kidney, liver, and heart transplant recipients. J Pharm Biomed Anal 53(4):997\u20131002. https:\/\/doi.org\/10.1016\/j.jpba.2010.06.022","journal-title":"J Pharm Biomed Anal"},{"key":"3920_CR20","doi-asserted-by":"publisher","first-page":"726784","DOI":"10.3389\/fphar.2021.726784","volume":"12","author":"L Srinivas","year":"2021","unstructured":"Srinivas L, Gracious N, Nair RR (2021) Pharmacogenetics based dose prediction model for initial tacrolimus dosing in renal transplant recipients. Front Pharmacol 12:726784. https:\/\/doi.org\/10.3389\/fphar.2021.726784","journal-title":"Front Pharmacol"},{"issue":"3","key":"3920_CR21","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1002\/jcph.1325","volume":"59","author":"O Campagne","year":"2019","unstructured":"Campagne O, Mager DE, Tornatore KM (2019) Population pharmacokinetics of tacrolimus in transplant recipients: what did we learn about sources of interindividual variabilities? J Clin Pharmacol 59(3):309\u2013325. https:\/\/doi.org\/10.1002\/jcph.1325","journal-title":"J Clin Pharmacol"},{"issue":"e1","key":"3920_CR22","doi-asserted-by":"publisher","first-page":"e12","DOI":"10.1136\/ejhpharm-2018-001764","volume":"27","author":"Y Gong","year":"2020","unstructured":"Gong Y, Yang M, Sun Y, Li J, Lu Y, Li X (2020) Population pharmacokinetic analysis of tacrolimus in Chinese cardiac transplant recipients. Eur J Hosp Pharm 27(e1):e12\u2013e18. https:\/\/doi.org\/10.1136\/ejhpharm-2018-001764","journal-title":"Eur J Hosp Pharm"},{"issue":"3","key":"3920_CR23","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1097\/tp.0000000000000384","volume":"99","author":"I Robertsen","year":"2015","unstructured":"Robertsen I, \u00c5sberg A, Inger\u00f8 AO, Vethe NT, Bremer S, Bergan S, Midtvedt K (2015) Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. Transplantation 99(3):528\u2013532. https:\/\/doi.org\/10.1097\/tp.0000000000000384","journal-title":"Transplantation"},{"key":"3920_CR24","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.biopha.2018.03.054","volume":"102","author":"X Zhang","year":"2018","unstructured":"Zhang X, Lin G, Tan L, Li J (2018) Current progress of tacrolimus dosing in solid organ transplant recipients: pharmacogenetic considerations. Biomed Pharmacother 102:107\u2013114. https:\/\/doi.org\/10.1016\/j.biopha.2018.03.054","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"3920_CR25","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1002\/cpt.1629","volume":"107","author":"TA Miano","year":"2020","unstructured":"Miano TA, Flesch JD, Feng R, Forker CM, Brown M, Oyster M, Kalman L, Rushefski M, Cantu E 3rd, Porteus M, Yang W, Localio AR, Diamond JM, Christie JD, Shashaty MGS (2020) Early tacrolimus concentrations after lung transplant are predicted by combined clinical and genetic factors and associated with acute kidney injury. Clin Pharmacol Ther 107(2):462\u2013470. https:\/\/doi.org\/10.1002\/cpt.1629","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"3920_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1177\/0091270003262108","volume":"44","author":"H Zheng","year":"2004","unstructured":"Zheng H, Zeevi A, Schuetz E, Lamba J, McCurry K, Griffith BP, Webber S, Ristich J, Dauber J, Iacono A, Grgurich W, Zaldonis D, McDade K, Zhang J, Burckart GJ (2004) Tacrolimus dosing in adult lung transplant patients is related to cytochrome P4503A5 gene polymorphism. J Clin Pharmacol 44(2):135\u2013140. https:\/\/doi.org\/10.1177\/0091270003262108","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"3920_CR27","doi-asserted-by":"publisher","first-page":"141","DOI":"10.2165\/11317350-000000000-00000","volume":"49","author":"CE Staatz","year":"2010","unstructured":"Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: part I. Clin Pharmacokinet 49(3):141\u2013175. https:\/\/doi.org\/10.2165\/11317350-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"3920_CR28","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jmoldx.2023.06.008","volume":"25","author":"VM Pratt","year":"2023","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, Gaedigk A, Hachad H, Ji Y, Kalman LV, Ly RC, Moyer AM, Scott SA, van Schaik RHN, Whirl-Carrillo M, Weck KE (2023) CYP3A4 and CYP3A5 genotyping recommendations: a joint consensus recommendation of the association for molecular pathology, clinical pharmacogenetics implementation consortium, college of American pathologists, Dutch pharmacogenetics working group of the royal Dutch pharmacists association, European society for pharmacogenomics and personalized therapy, and pharmacogenomics knowledgebase. J Mol Diagn 25(9):619\u2013629. https:\/\/doi.org\/10.1016\/j.jmoldx.2023.06.008","journal-title":"J Mol Diagn"},{"issue":"1","key":"3920_CR29","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-013-1584-7","volume":"70","author":"E St\u00f8rset","year":"2014","unstructured":"St\u00f8rset E, Holford N, Midtvedt K, Bremer S, Bergan S, \u00c5sberg A (2014) Importance of hematocrit for a tacrolimus target concentration strategy. Eur J Clin Pharmacol 70(1):65\u201377. https:\/\/doi.org\/10.1007\/s00228-013-1584-7","journal-title":"Eur J Clin Pharmacol"},{"issue":"4","key":"3920_CR30","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s40262-019-00846-1","volume":"59","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Hunault CC, Huitema ADR, De Lange DW, Van Maarseveen EM (2020) Clinical pharmacokinetics and impact of hematocrit on monitoring and dosing of tacrolimus early after heart and lung transplantation. Clin Pharmacokinet 59(4):403\u2013408. https:\/\/doi.org\/10.1007\/s40262-019-00846-1","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"3920_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1007\/s40262-019-00854-1","volume":"59","author":"MA Sikma","year":"2020","unstructured":"Sikma MA, Van Maarseveen EM, Hunault CC, Moreno JM, Van de Graaf EA, Kirkels JH, Verhaar MC, Grutters JC, Kesecioglu J, De Lange DW, Huitema ADR (2020) Unbound plasma, total plasma, and whole-blood tacrolimus pharmacokinetics early after thoracic organ transplantation. Clin Pharmacokinet 59(6):771\u2013780. https:\/\/doi.org\/10.1007\/s40262-019-00854-1","journal-title":"Clin Pharmacokinet"},{"issue":"1","key":"3920_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00228-012-1300-z","volume":"69","author":"I Oteo","year":"2013","unstructured":"Oteo I, Lukas JC, Leal N, Suarez E, Valdivieso A, Gastaca M, Ortiz de Urbina J, Calvo R (2013) Tacrolimus pharmacokinetics in the early post-liver transplantation period and clinical applicability via Bayesian prediction. Eur J Clin Pharmacol 69(1):65\u201374. https:\/\/doi.org\/10.1007\/s00228-012-1300-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"9","key":"3920_CR33","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.2217\/pgs.14.75","volume":"15","author":"V Guy-Viterbo","year":"2014","unstructured":"Guy-Viterbo V, Baudet H, Elens L, Haufroid V, Lacaille F, Girard M, Debray D, Chardot C, Reding R, Wallemacq P, Musuamba F (2014) Influence of donor-recipient CYP3A4\/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics 15(9):1207\u20131221. https:\/\/doi.org\/10.2217\/pgs.14.75","journal-title":"Pharmacogenomics"},{"issue":"6","key":"3920_CR34","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1592\/phco.27.6.825","volume":"27","author":"A Sansone-Parsons","year":"2007","unstructured":"Sansone-Parsons A, Krishna G, Martinho M, Kantesaria B, Gelone S, Mant TG (2007) Effect of oral posaconazole on the pharmacokinetics of cyclosporine and tacrolimus. Pharmacotherapy 27(6):825\u2013834. https:\/\/doi.org\/10.1592\/phco.27.6.825","journal-title":"Pharmacotherapy"},{"issue":"2","key":"3920_CR35","doi-asserted-by":"publisher","first-page":"E163","DOI":"10.1111\/j.1399-0012.2010.01373.x","volume":"25","author":"MR Kramer","year":"2011","unstructured":"Kramer MR, Amital A, Fuks L, Shitrit D (2011) Voriconazole and itraconazole in lung transplant recipients receiving tacrolimus (FK 506): efficacy and drug interaction. Clin Transplant 25(2):E163-167. https:\/\/doi.org\/10.1111\/j.1399-0012.2010.01373.x","journal-title":"Clin Transplant"},{"issue":"9","key":"3920_CR36","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1111\/ajt.14232","volume":"17","author":"T Vanhove","year":"2017","unstructured":"Vanhove T, Bouwsma H, Hilbrands L, Swen JJ, Spriet I, Annaert P, Vanaudenaerde B, Verleden G, Vos R, Kuypers DRJ (2017) Determinants of the magnitude of interaction between tacrolimus and voriconazole\/posaconazole in solid organ recipients. Am J Transplant 17(9):2372\u20132380. https:\/\/doi.org\/10.1111\/ajt.14232","journal-title":"Am J Transplant"},{"issue":"12","key":"3920_CR37","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.1592\/phco.26.12.1730","volume":"26","author":"AH Saad","year":"2006","unstructured":"Saad AH, DePestel DD, Carver PL (2006) Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 26(12):1730\u20131744. https:\/\/doi.org\/10.1592\/phco.26.12.1730","journal-title":"Pharmacotherapy"},{"issue":"13","key":"3920_CR38","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1517\/14656566.6.13.2231","volume":"6","author":"PO Gubbins","year":"2005","unstructured":"Gubbins PO, Amsden JR (2005) Drug-drug interactions of antifungal agents and implications for patient care. Expert Opin Pharmacother 6(13):2231\u20132243. https:\/\/doi.org\/10.1517\/14656566.6.13.2231","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"3920_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1111\/bcp.14398","volume":"87","author":"S Chanoine","year":"2021","unstructured":"Chanoine S, Gautier-Veyret E, Pluchart H, Tonini J, Fonrose X, Claustre J, Bedouch P, Stanke-Labesque F (2021) Tablets or oral suspension for posaconazole in lung transplant recipients? Consequences for trough concentrations of tacrolimus and everolimus. Br J Clin Pharmacol 87(2):427\u2013435. https:\/\/doi.org\/10.1111\/bcp.14398","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"3920_CR40","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1111\/bcpt.12176","volume":"114","author":"N Han","year":"2014","unstructured":"Han N, Ha S, Yun HY, Kim MG, Min SI, Ha J, Lee JI, Oh JM, Kim IW (2014) Population pharmacokinetic-pharmacogenetic model of tacrolimus in the early period after kidney transplantation. Basic Clin Pharmacol Toxicol 114(5):400\u2013406. https:\/\/doi.org\/10.1111\/bcpt.12176","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1","key":"3920_CR41","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/FTD.0b013e31829f1ab8","volume":"36","author":"TK Bergmann","year":"2014","unstructured":"Bergmann TK, Hennig S, Barraclough KA, Isbel NM, Staatz CE (2014) Population pharmacokinetics of tacrolimus in adult kidney transplant patients: impact of CYP3A5 genotype on starting dose. Ther Drug Monit 36(1):62\u201370. https:\/\/doi.org\/10.1097\/FTD.0b013e31829f1ab8","journal-title":"Ther Drug Monit"},{"issue":"8","key":"3920_CR42","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1111\/ctr.12763","volume":"30","author":"MG Tanzi","year":"2016","unstructured":"Tanzi MG, Undre N, Keirns J, Fitzsimmons WE, Brown M, First MR (2016) Pharmacokinetics of prolonged-release tacrolimus and implications for use in solid organ transplant recipients. Clin Transplant 30(8):901\u2013911. https:\/\/doi.org\/10.1111\/ctr.12763","journal-title":"Clin Transplant"},{"issue":"1","key":"3920_CR43","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/phar.2480","volume":"41","author":"L Schumacher","year":"2021","unstructured":"Schumacher L, Leino AD, Park JM (2021) Tacrolimus intrapatient variability in solid organ transplantation: a multiorgan perspective. Pharmacotherapy 41(1):103\u2013118. https:\/\/doi.org\/10.1002\/phar.2480","journal-title":"Pharmacotherapy"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03920-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03920-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03920-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T04:43:58Z","timestamp":1764909838000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03920-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,23]]},"references-count":43,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["3920"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03920-9","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,23]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Committees of the The First Affiliated Hospital of Guangzhou Medical University (ES-2023-K010). Informed consent was obtained from all participants included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients signed informed consent regarding publishing their data.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}